Modulation of paracetamol-induced hepatotoxicity by phosphodiesterase isozyme inhibition in rats: A preliminary study

Journal of Basic and Clinical Physiology and Pharmacology

Volumn 24, Issue 1, 2013, Pages 73-79

  Ekor, Martins ^a,b   Odewabi, Adesina O ^b   Kale, Oluwafemi E ^b   Bamidele, Titilayo O ^c   Adesanoye, Omolola A ^d   Farombi, Ebenezer O ^d  

^a UNIVERSITY OF CAPE COAST   (Ghana)

^b OLABISI ONABANJO UNIVERSITY   (Nigeria)

^c NASARAWA STATE UNIVERSITY   (Nigeria)

^d UNIVERSITY OF IBADAN   (Nigeria)

Author keywords

Aminophylline; Hepatotoxicity; Paracetamol; Phosphodiesterase; Sildenafil

Indexed keywords

ALANINE AMINOTRANSFERASE; AMINOPHYLLINE; ASPARTATE AMINOTRANSFERASE; CYCLIC GMP; GLUTATHIONE; GUANOSINE PHOSPHATE; ISOENZYME; PARACETAMOL; PHOSPHODIESTERASE V; SILDENAFIL; SODIUM CHLORIDE; TRIACYLGLYCEROL;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CLINICAL EVALUATION; CONTROLLED STUDY; ENZYME INHIBITION; LIPID PEROXIDATION; LIVER FATTY DEGENERATION; LIVER NECROSIS; LIVER TOXICITY; MALE; NONHUMAN; RAT; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84877947737     PISSN: 07926855     EISSN: 21910286     Source Type: Journal    
DOI: 10.1515/jbcpp-2012-0043     Document Type: Article

References (51)

1. Houslay MD. PDE4 cAMP-specific phosphodiesterases. Prog Nucleic Acid Res Mol Biol 2001;69:249-315.
2. Soderling SH, Beavo JA. Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions. Curr Opin Cell Biol Rev 2000;12:174-9.
3. Deree J, Martins JO, Melbostad H, Loomis WH, Coimbra R. Insights into the regulation of TNF-〈production in human mononuclear cells: the effects of non-specific phosphodiesterase inhibition. Clinics (Sao Paulo) 2008;63:321-8.
4. Matsumoto T, Kobayashi T, Kamata K. Phosphodiesterases in the vascular system. J Smooth Muscle Res 2003;39:67-86.
5. Prisant LM. Phosphodiesterase-5 inhibitors and their hemodynamic effects. Curr Hypertens Rep 2006;8:345-51.
6. Francis SH, Blount MA, Corbin JD. Mammalian cyclic nucleotide phosphodiesterases: molecular mechanisms and physiological functions. Physiol Rev 2011;91:651-90.
7. Iwakiri Y, Groszmann RJ. The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule. Hepatology 2006;43:S121-31.
8. Iwakiri Y, Groszmann RJ. Vascular endothelial dysfunction in cirrhosis. J Hepatol 2007;46:927-34.
9. Malyshev E, Tazi KA, Moreau R, Lebrec D. Discrepant effects of inducible nitric oxide synthase modulation on systemic and splanchnic endothelial nitric oxide synthase activity and expression in cirrhotic rats. J Gastroenterol Hepatol 2007;22:2195-201.
10. Rodriguez-Vilarrupla A, Fernandez M, Bosch J, Garcia-Pagan JC. Current concepts on the pathophysiology of portal hypertension. Ann Hepatol 2007;6:28-36.
11. Zipprich A. Hemodynamics in the isolated cirrhotic liver. J Clin Gastroenterol 2007;41:S254-8.
12. Davies NA, Hodges SJ, Pitsillides AA, Mookerjee RP, Jalan R, Mehdizadeh S. Hepatic guanylate cyclase activity is decreased in a model of cirrhosis: a quantitative cytochemistry study. FEBS Lett 2006;580:2123-8.
13. Loureiro-Silva MR, Iwakiri Y, Abraldes JG, Haq O, Groszmann RJ. Increased phosphodiesterase-5 expression is involved in the decreased vasodilator response to nitric oxide in cirrhotic rat livers. J Hepatol 2006;44:886-93.
14. Tsai MH, Iwakiri Y, Cadelina G, Sessa WC, Groszmann RJ. Mesenteric vasoconstriction triggers nitric oxide overproduction in the superior mesenteric artery of portal hypertensive rats. Gastroenterology 2003;125:1452-61.
15. Laskin DL, Heck DE, Gardner CR, Feder LS, Laskin JD. Distinct patterns of nitric oxide production in hepatic macrophages and endothelial cells following acute exposure of rats to endotoxin. J Leukoc Biol 1994;56:751-8.
16. Laskin DL, Rodriguez del Valle M, Heck DE, Hwang SM, Ohnishi ST, Durham SK, et al. Hepatic nitric oxide production following acute endotoxemia in rats is mediated by increased nitric oxide synthase gene expression. Hepatology 1995;22:223-34.
17. Thiemermann C, Ruetten H, Wu CC, Vane Jr. The multiple organ dysfunction syndrome caused by endotoxin in the rat: attenuation of liver dysfunction by inhibitors of nitric oxide synthase. Br J Pharmacol 1995;116:2845-51.
18. Chamulitrat W, Blazka ME, Jordan SJ, Luster MI, Mason RP. Tumor necrosis factor-〈and nitric oxide production in endotoxin-primed rats administered carbon tetrachloride. Life Sci 1995;24:2273-80.
19. Dalmau M, Joaquin M, Nakamura T, Bartrons R, Gil J. Nitric oxide inhibits DNA synthesis and induces activation of poly(ADPribose) polymerase in cultured rat hepatocytes. Exp Cell Res 1996;228:14-8.
20. Shinagawa T, Yoshioka K, Kakumu S, Wakita T, Ishikawa T, Itoh Y, et al. Apoptosis in cultured rat hepatocytes: the effects of tumour necrosis factor-〈and interferon-©. J Pathol 1991;165:247-53.
21. Morales-Ruiz M, Cejudo-Martin P, Fernandez-Varo G, Tugues S, Ros J, Angeli P, et al. Transduction of the liver with activated Akt normalizes portal pressure in cirrhotic rats. Gastroenterology 2003;125:522-31.
22. Zafra C, Abraldes JG, Turnes J, Berzigotti A, Fernandez M, Garca-Pagan JC, et al. Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis. Gastroenterology 2004;126:749-55.
23. Trebicka J, Hennenberg M, Laleman W, Shelest N, Biecker E, Schepke M, et al. Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase. Hepatology 2007;46:242-53.
24. Laleman W, Van Landeghem L, Van der Elst I, Zeegers M, Fevery J, Nevens F. Nitroflurbiprofen, a nitric oxide-releasing cyclooxygenase inhibitor, improves cirrhotic portal hypertension in rats. Gastroenterology 2007;132:709-19.
25. Deibert P, Schumacher YO, Ruecker G, Opitz OG, Blum HE, Rossle M, et al. Effect of vardenafil, an inhibitor of phosphodiesterase-5, on portal haemodynamics in normal and cirrhotic liver-results of a pilot study. Aliment Pharmacol Ther 2006;23:121-8.
26. Halverscheid L, Deibert P, Schmidt R, Blum HE, Dunkern T, Pannen BH, et al. Phosphodiesterase-5 inhibitors have distinct effects on the hemodynamics of the liver. BMC Gastroenterol 2009;9:69. doi:10.1186/1471-230X-9-69.
27. Colle I, De Vriese AS, Van Vlierberghe H, Lameire NH, DeVos M. Systemic and splanchnic haemodynamic effects of sildenafil in an in vivo animal model of cirrhosis support for a risk in cirrhotic patients. Liver Int 2004;24:63-8.
28. Wang YW, Lin HC, Yang YY, Hou MC, Lee SD. Sildenafil decreased pulmonary arterial pressure but may have exacerbated portal hypertension in a patient with cirrhosis and portopulmonary hypertension. J Gastroenterol 2006;41:593-7.
29. Tzathas C, Christidou A, Ladas SD. Sildenafil (Viagra) is a risk factor for acute variceal bleeding. Am J Gastroenterol 2002;97:1856.
30. Finley DS, Lugo B, Ridgway J, Teng W, Imagawa DK. Fatal variceal rupture after sildenafil use: report of a case. Curr Surg 2005;62:55-6.
31. Gardner CR, Heck DE, Yang CS, Thomas PE, Zhang XJ, Degeorge GL, et al. Role of nitric oxide in acetaminophen-induced hepatotoxicity in the rat. Hepatology 1998;26:748-54.
32. Committee for the Update of the Guide for the Care and Use of Laboratory Animals. Guide for the care and use of laboratory animals, 8th ed. Washington, DC: National Academy of Sciences, National Academies Press, 2011.
33. Chiang CE, Luk HN, Wang TM, Ding PY. Effects of sildenafil on cardiac repolarization. Cardiovasc Res 2002;55:290-9.
34. Zhang L, Zhang RL, Wang Y, Zhang C, Zhang ZG, Meng H, et al. Functional recovery in aged and young rats after embolic stroke: treatment with a phosphodiesterase type 5 inhibitor. Stroke 2005;36:847-52.
35. Reitman S, Frankel SA. Colorimetric method for the determination of serum glutamate-oxaloacetate and pyruvate transaminases. Am J Clin Pathol 1957;28:56-63.
36. Gornall AG, Bardawill CJ, David MM. Determination of serum proteins by means of the Biuret reaction. J Biol Chem 1949;177:751.
37. Doumas BT, Watson WA, Biggs HG. Albumin standards and the measurement of serum albumin with bromocresol green reaction. Clin Chem 1971;22:616-22.
38. Trinder P. Quantitative determination of triglyceride using GPO-PAP method. Ann Clin Biochem 1969;6:24-7.
39. Beutler E, Duron O, Kelly BM. Improved method for the determination of blood glutathione. J Lab Clin Med 1963;61:882-8.
40. Varshney R, Kale RK. Effect of calmodulin antagonist on radiation induced lipid peroxidation in microsomes. Int J Radiat Biol 1990;58:733-43.
41. Levine G. A guide to SPSS for analysis of variance. Hillsdale, NJ: Lawrence Erlbaum Associates Inc. Publishers, 1991:65-7.
42. Wang JF, Greenberg SS, Spitzer JJ. Chronic alcohol administration stimulates nitric oxide formation in the rat liver with and without pretreatment by lipopolysaccharide. Alcohol Clin Exp Res 1995;19:387-93.
43. Blei AT. Portal hypertension and its complications. Curr Opin Gastroenterol 2007;23:275-82.
44. DeLeve LD. Hepatic microvasculature in liver injury. Semin Liver Dis 2007;27:390-400.
45. Sessa WC. eNOS at a glance. J Cell Sci 2004;117:2427-9.
46. Bellamy TC, Wood J, Garthwaite J. On the activation of soluble guanylyl cyclase by nitric oxide. Proc Natl Acad Sci USA 2002;99:507-10.
47. Kang KK, Yu JY, Yoo M, Kwon JW. The effect of DA-8159, a novel PDE5 inhibitor, on erectile function in the rat model of hypercholesterolemic erectile dysfunction. Int J Impot Res 2005;17:409-16.
48. Tani T, Uehara K, Sudo T, Marukawa K, Yasuda Y, Kimura Y. Cilostazol, a selective type III phosphodiesterase inhibitor, decreases triglyceride and increases HDL cholesterol levels by increasing lipoprotein lipase activity in rats. Atherosclerosis 2000;152:299-305.
49. Y ildiz H, Durmus AS, Simsek H, Yaman M. Dose-dependent protective effect of sildenafil citrate on testicular injury after torsion/detorsion in rats. Andrologia 2012;44(Suppl 1): 300-6.
50. Perk H, Armagan A, Naz i roglu M, Soyupek S, Hoscan MB, Sutcu R, et al. Sildenafil citrate as a phosphodiesterase inhibitor has an antioxidant effect in the blood of men. J Clin Pharm Ther 2008;33:635-40.
51. Tsukagoshi H, Shimizu Y, Iwamae S, Hisada T, Ishizuka T, Iizuka K, et al. Evidence of oxidative stress in asthma and COPD: potential inhibitory effect of theophylline. Respir Med 2000;94:584-8.